FDA approves Roche's OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and ...

Retrieved on: 2020-12-14 20:15:00

Tags for this article:

Click the tags to see associated articles and topics

FDA approves Roche's OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and .... View article details on hiswai:

Excerpt

Basel, 14 December 2020 - <b>Roche</b> (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has ...

Article found on: www.globenewswire.com